There is one clinical trial.
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
Nasopharyngeal Carcinoma Cyclin-dependent Kinase 12 Mutated Tumors Basal Cell Carcinoma (Unresectable or Metastatic) Sarcomatoid Renal Cell Carcinoma Clear Cell Ovarian or Endometrial Carcinoma Anal Carcinoma Squamous Cell Penile Carcinoma DNA Polymerase Epsilon Mutated Tumors (P286R and V411L) Carcinoma, Merkel Cell Carcinoma Neoplasms Carcinoma, Squamous Cell Carcinoma, Renal Cell Small Cell Lung Carcinoma Mesothelioma Nasopharyngeal Carcinoma Carcinoma, Basal Cell Esophageal Squamous Cell Carcinoma Endometrial Neoplasms null --- P286R ---
Description: Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug up to 30 days after last dose of study drug.
Measure: Number of treatment-emergent adverse events Time: Up to approximatley 25 monthsDescription: Maximum observed plasma concentration
Measure: Cmax of INCB099318 Time: Up to approximately 3 monthsDescription: Time to maximum plasma concentration
Measure: tmax of INCB099318 Time: Up to approximately 3 monthsDescription: Minimum observed plasma concentration over the dose interval
Measure: Cmin of INCB099318 Time: Up to approximately 3 monthsDescription: Area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t
Measure: AUC0-t of INCB099318 Time: Up to approximately 3 monthsDescription: Apparent terminal-phase disposition half-life
Measure: t½ of INCB099318 Time: Up to approximately 3 monthsDescription: Terminal elimination rate constant
Measure: λz of INCB099318 Time: Up to approximately 3 monthsDescription: Oral dose clearance
Measure: CL/F of INCB099318 Time: Up to approximately 3 monthsDescription: Apparent oral dose volume of distribution
Measure: Vz/F of INCB099318 Time: Up to approximately 3 months